GFGuotao Fu

Guotao Fu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guotao Fu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Gao

    The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

    1 shared publication
  • Chengxing Shen

    Department of Cardiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine , Shanghai

    1 shared publication
  • Chenyang Jiang

    Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China

    1 shared publication
  • Fu Yi

    Department of Cardiology, Xijing Hospital, The Fourth Military Medical University , Changle west road, Xi'an 710032

    1 shared publication
  • Haitao Liu

    Department of Cardiology, Xijing Hospital, The Fourth Military Medical University , Changle west road, Xi'an 710032

    1 shared publication
  • Haixiong Wang

    Shanxi Key Laboratory of Heart Failure Precision Medicine, Cardiovascular Hospital Affiliated to Shanxi Medical University, 030024 Taiyuan, Shanxi, China

    1 shared publication

Latest Publications

  • Open Access

    Three-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study

    by Tingting Zhang, Xueni He, Guotao Fu, Haitao Liu, Fu Yi, Jianzheng Liu, Ping Wang, Zhengquan Chen, Xianxian Zhao, Huimin Chu, et al.

    The long-term impact of left atrial appendage occlusion (LAAO) plus ablation for atrial fibrillation remains controversial. The present study aims to compare the three-year clinical outcomes of LAAO patients with or without one-staged ablation. The RECORD study (NCT03917563) was a prospective registry conducted in 39 participating sites in China between 1 April 2019 and 31 October 2020, which consecutively enrolled 3082 patients who successfully received the WATCHMAN LAAO device. The current study compared patients who received LAAO only to patients who underwent LAAO plus ablation. A 1:1 propensity score matching was performed to attenuate confounding. The primary outcome was a composite endpoint of cardiovascular death, stroke, and systemic embolism at 3-year. 1633/2928 (55.8%) patients received LAAO only and 1295/2928 (44.2%) received LAAO plus ablation. After propensity score matching, 1016/2032 (50.0%) were in the LAAO group and 1016/2032 (50.0%) in the LAAO plus ablation group. The mean ± SD age was 68.8 ± 9.3 years, with 815 (40.1%) participants being female. The mean ± SD CHA2DS2-VASc and HAS-BLED scores at baseline were 3.9 ± 1.8 and 2.4 ± 1.1, respectively. At three-year, compared to LAAO only, LAAO plus ablation was associated with a lower risk of cardiovascular death, stroke, systemic embolism (6.9%vs.10.4%, HRPSM:0.66, 95%CI: 0.49–0.89, P = 0.007), which was driven mainly by the lower risk of cardiovascular death (3.7% vs. 7.3%, HRPSM: 0.50, 95%CI: 0.34–0.74, P = 0.001). No significant between-group differences were noted for BARC-defined bleeding. LAAO plus ablation was associated with a lower risk of a composite of cardiovascular death, stroke, and systemic embolism than LAAO only at 3-year. However, given the observational nature of the current study, the results should be considered as hypothesis-generating only.